

Mandana Nikpour

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5547131/mandana-nikpour-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

1,607
citations

22
h-index

38
g-index

82
ext. papers

2,218
ext. citations

4.5
avg, IF

4.61
L-index

#	Paper	IF	Citations
74	Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 53, 151973	5.3	0
73	Not at targetS prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 70	5.7	1
72	Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 103	5.7	0
71	How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e119	2.4	2
70	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
69	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 495-512	5.3	3
68	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. <i>Chest</i> , 2021 , 160, 2158-2162	5.3	1
67	Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes. <i>Arthritis Care and Research</i> , 2021 , 73, 732-741	4.7	8
66	Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 299-309	5.3	6
65	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021 , 60, 5185-5193	3.9	1
64	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
63	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 142-148	2.2	
62	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 142-148	2.2	0
61	Response to: Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?Sby Chessa. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
60	High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	6
59	Safety of Intra-articular Corticosteroid Injection. <i>Radiology</i> , 2020 , 294, 720-722	20.5	0
58	Screening for pulmonary arterial hypertension in systemic sclerosis: Now or never!. <i>European Journal of Rheumatology</i> , 2020 , 7, S187-S192	1.7	1

57	Hydroxychloroquine in dermatology: New perspectives on an old drug. <i>Australasian Journal of Dermatology</i> , 2020 , 61, e150-e157	1.3	11
56	The clinical and economic burden of systemic sclerosis related interstitial lung disease. <i>Rheumatology</i> , 2020 , 59, 1878-1888	3.9	4
55	Cancer and scleroderma: recent insights. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 479-487	5.3	3
54	Performance of the 2017 EUSTAR activity index in an scleroderma cohort. <i>Clinical Rheumatology</i> , 2020 , 39, 3701-3705	3.9	0
53	Response to: Differentiating disease activity from damage in systemic sclerosis: it's still early days! by Jain and Sharma. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e99	2.4	1
52	Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to: Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome? by Coudrec. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e100	2.4	3
51	Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020 , 72, 1625-1635	4.7	7
50	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1289-1295	4.7	12
49	Response to: Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter by Sbeih. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e149	2.4	0
48	Correspondence regarding research letter to the editor by Mathian, Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
47	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology</i> , 2019 , 1, e95-e102	14.2	26
46	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 807-816	2.4	16
45	Defining primary systemic sclerosis heart involvement: A scoping literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 874-887	5.3	16
44	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019 , 10, 4955	17.4	46
43	How do surgeons trade-off between patient outcomes and risk of complications in total knee arthroplasty? a discrete choice experiment in Australia. <i>BMJ Open</i> , 2019 , 9, e029406	3	2
42	The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. <i>BMC Pulmonary Medicine</i> , 2019 , 19, 226	3.5	2
41	Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. <i>Arthritis Research and Therapy</i> , 2019 , 21, 299	5.7	12
40	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 425-433	2.3	14

39	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
38	Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 221-239	5.3	21
37	CD39 and CD73 activity are protective in a mouse model of antiphospholipid antibody-induced miscarriages. <i>Journal of Autoimmunity</i> , 2018 , 88, 131-138	15.5	13
36	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 249-252	2.3	25
35	The role of inflammatory markers in assessment of disease activity in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 126-134	2.2	9
34	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. <i>Arthritis Research and Therapy</i> , 2017 , 19, 42	5.7	37
33	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 62	5.7	59
32	Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 188-195	2.3	4
31	A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1728-1750	2.3	10
30	Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2017 , 19, 122	5.7	33
29	Measures of disease status in systemic sclerosis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 473-487	5.3	13
28	Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 130-137	2.2	2
27	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1615-21	2.4	235
26	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. <i>Arthritis Research and Therapy</i> , 2016 , 18, 260	5.7	29
25	The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 246	5.7	10
24	Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. <i>Scientific Reports</i> , 2016 , 6, 29909	4.9	22
23	Using discrete choice experiments as a decision aid in total knee arthroplasty: study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 416	2.8	9
22	Independent association of glucocorticoids with damage accrual in SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000157	4.6	53

21	Systemic sclerosis: The need for structured care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016 , 30, 3-21	5.3	9
20	Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. <i>BMC Pulmonary Medicine</i> , 2016 , 16, 134	3.5	25
19	Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 170-176	2.2	11
18	Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 79-84	2.2	7
17	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 7	5.7	63
16	Musculoskeletal Manifestations of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 507-18	2.4	29
15	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S131-5	2.2	22
14	The need to define treatment goals for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 567-71	8.1	33
13	Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 131-7	5.3	41
12	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2013 , 15, R193	5.7	37
11	Assessment of coronary risk based on cumulative exposure to lipids in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 2006-14	4.1	4
10	The assessment of disease activity in rheumatic diseases. <i>International Journal of Rheumatology</i> , 2013 , 2013, 275691	2	
9	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3052-3		13
8	Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. <i>Arthritis Research and Therapy</i> , 2011 , 13, R211	5.7	108
7	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R156	5.7	61
6	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R125	5.7	20
5	Epidemiology of systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010 , 24, 857-69	5.3	76
4	Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 288-94	4.1	26

3	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1152-8		90
2	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009 , 11, 248-54	4.9	32
1	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 329-54, vii-viii	2.4	75